Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2022 Mar 24;399(10331):1224. doi: 10.1016/S0140-6736(22)00363-4

No point in travel bans if countries with poor surveillance are ignored

Wolfgang Preiser a, Susan Engelbrecht a, Tongai Maponga a
PMCID: PMC8947807  PMID: 35339220

Marc Mendelson and colleagues1 argue strongly against travel bans to contain newly recognised SARS-CoV-2 variants of concern. We would like to add another aspect: ignoring countries with poor surveillance systems.

South Africa has good epidemiological and genomic surveillance, but many other countries do not. Within 2 days of return to South Africa from Tanzania in January, 2021, a traveller developed clinical symptoms and tested positive for SARS-CoV-2 by PCR. Sequencing using published methods2 identified the virus as the beta variant of concern,3 highly likely to have been acquired in Tanzania during its second epidemic wave.4

This case highlights the potential for a variant of concern to be introduced from a country that had not reported its presence. Until Dec 23, 2021, Tanzania has not uploaded a single SARS-CoV-2 genetic sequence to GISAID. In fact, Tanzania had not been reporting COVID-19 case numbers at all between May, 2020, and July, 2021, linked to a denialist official stance.4

Tanzania's second wave in early 2021 might have been linked to the beta variant with the traveller acting as a sentinel.5 Although several countries in southern Africa were listed as so-called areas of variants of concern by Germany in early 2021, Tanzania remained a so-called risk area until being declared a high incidence area from mid-March, 2021.

Perceived as punishment for countries conducting genomic surveillance and reporting openly, the illogical application of travel bans could act as a deterrent to conducting genomic surveillance and, thus, foil their very objective.

For more on GISAID see https://www.gisaid.org

Acknowledgments

We declare no competing interests.

References

  • 1.Mendelson M, Venter F, Moshabela M, et al. The political theatre of the UK's travel ban on South Africa. Lancet. 2021;398:2211–2213. doi: 10.1016/S0140-6736(21)02752-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Engelbrecht S, Delaney K, Kleinhans B, et al. Multiple early introductions of SARS-CoV-2 to Cape Town, South Africa. Viruses. 2021;13:526. doi: 10.3390/v13030526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438–443. doi: 10.1038/s41586-021-03402-9. [DOI] [PubMed] [Google Scholar]
  • 4.Buguzi S. Covid-19: counting the cost of denial in Tanzania. BMJ. 2021;373 doi: 10.1136/bmj.n1052. [DOI] [PubMed] [Google Scholar]
  • 5.Günther S, Emmerich P, Laue T, et al. Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis. 2000;6:466–476. doi: 10.3201/eid0605.000504. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Lancet (London, England) are provided here courtesy of Elsevier

RESOURCES